Global and China Monoclonal Antibody Industry Report, 2013 - 2017
Published Date » 2013-12-23
No. Of Pages » 118
Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.
Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).
The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.
Propelled by the optimistic market prospect, advancement of monoclonal antibody technologies and the upcoming patent expiration of several key monoclonal antibody agents, the research and industrialization of monoclonal antibody agents has become a global investment highlight, wherein the future market competition will be evident.
In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014.
In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013.
In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.
However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year).
Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013.
Table of Content
1 Overview of Monoclonal Antibody Industry
1.3 Technological Development
2 Overview of Global Monoclonal Antibody Industry
2.1 Status Quo
2.2 Market Size
2.3 Competition Pattern
2.4 Development Prospect and Prediction
2.4.1 Market Size
2.4.2 Competition Pattern
2.4.3 R & D Trend
3 Chinese Monoclonal Antibody Market
3.1 Status Quo
3.2 Market Size
3.3 Market Segments
3.3.6 Recombinant Human Tumor Necrosis Factor Receptor Type II - Antibody Fusion Protein
3.4 Competition Pattern
3.5 Development Prospect
4 Key Foreign Monoclonal Antibody Agent Enterprises
4.1 Roche Pharmaceuticals
4.1.3 Revenue Structure
4.1.4 R & D and Investment
4.1.5 Monoclonal Antibody Business (Genentech)
4.1.6 Business in China
4.2 Johnson & Johnson
4.2.3 Revenue Structure
4.2.4 R & D and Investment
4.2.5 Monoclonal Antibody Business
4.2.6 Business in China
4.3.3 Revenue Structure
4.3.4 R & D and Investment
4.3.5 Monoclonal Antibody Business
4.3.6 Business in China
4.4.3 Revenue Structure
4.4.4 R & D and Investment
4.4.5 Monoclonal Antibody Business
4.4.6 Business in China
4.5.2 Revenue Structure
4.5.3 R & D and Investment
4.5.4 Monoclonal Antibody Business
4.5.5 Business in China
4.6.3 Revenue Structure
4.6.4 R & D and Investment
4.6.5 Monoclonal Antibody Business
4.6.6 Business in China
5 Key Chinese Monoclonal Antibody Agent Enterprises
5.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd.
5.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
5.1.3 Shanghai Zhangjiang Biotech Co., Ltd.
5.1.4 Shanghai CP GuoJian Biotech Academy
5.1.5 Shanghai Guosheng Pharmaceutical Co., Ltd.
5.2 Beijing Biotech Pharmaceutical Co., Ltd.
5.2.2 Competitive Edges
5.2.3 Development Prospect
5.3 Chengdu Huasun Group Co., Ltd.
5.3.2 Chengdu Huasun Biotech Co., Ltd.
5.4 Shanghai Medipharm Biotech Co., Ltd.
5.4.2 Monoclonal Antibody Business
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.5.2 Monoclonal Antibody Business
5.6 Yunnan Walvax Biotechnology Co., Ltd.
5.6.2 Monoclonal Antibody Business
5.7 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.7.2 Monoclonal Antibody Business
5.8 Beijing SL Pharmaceutical Co., Ltd.
5.8.2 Monoclonal Antibody Business
5.9 Shenzhen Main Luck Pharmaceuticals Inc.
5.9.2 Monoclonal Antibody Business
5.10 Huahai Pharmaceutical Co., Ltd.
5.10.2 Monoclonal Antibody Business
6 Summary and Forecast
6.1 Comparison between Domestic and Foreign Companies
6.2 Market Forecast
List of Tables
List of Figures
Chocolate Market - North America Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
In sweets, chocolates are considered to be the most favorite treat for everyone. Chocolate can be defined as a processed sweetened food, having a major content of cocoa. It includes various types; such as with maximum cocoa content, is the dark chocolate, milk chocolates has the major content of milk and other different flavor. The demand of chocolate with consumer’s preference will have the direct impact on chocolate market in North America. United States has the maximum share in terms of volume for chocolate in North American market. The chocolate market is segmented as...
Sexually Transmitted Disease (STD) Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Sexually transmitted diseases (STD), also known as venereal diseases have significant probability of transmission among humans by means of human sexual behavior. These diseases can also spread through childbirth or breast feeding and by the shared use of needles. Diseases such as HIV, HPV, and Hepatitis B & C are forms of STDs. The increasing incidences of unprotected sex have led to an increase in the number of STD patients, which has ultimately led to a rise in the demand for STD diagnostic and treatment. Some of the drivers of this market are lack of sex related...
Prebiotics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Prebiotics are specific foods which increases the growth of bacteria and its activity in the digestive system. Prebiotics are defined as “A selectively fermented ingredient which allows specific changes, both in the composition and/or activity of the gastrointestinal microflora that confers benefits upon host well-being and health”. Probiotics are also engaged in same role however they are live micro-organism contained food. These foods directly deliver the micro-organisms to the intestine for the digestive activities. Prebiotics are indigestible dietary fibers...
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Select License type:
- Construction Sector in Russia H1 2014 Development Forecasts for 2014-2019
- Construction Sector in Hungary 2014 Development forecasts for 2014-2019
- Construction Sector in Slovenia 2014 Development Forecasts for 2014-2019
- Construction Sector in Bulgaria 2014 Development Forecasts for 2014-2019
- Non-public Hospitals Market in Poland 2014 Comparative Analysis by Voivodship and Development Prospects
- Retail in Russia 2014 - Regional focus. Market analysis and development forecasts for 2014-2019
- Global Umbilical Market: An Analysis (2013 - 2017)
- Global Stainless Steel Tube Market: Trends & Opportunities (2014-19)
- Global Graphene Market: Trends and opportunities (2014-2018)
- Shampoo, Conditioner and Hairstyling Products - US - April 2014
India is Facing a Cancer Crisis
Apr 15, 2014
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai. The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis. Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods. This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015. Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses. This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...
Ontarios thanks Sustainable Development Technology Canada for Clean Tech Ecosystem Movements
Apr 8, 2014
Sustainable Development Technology Canada has leveraged an extra $2.2 billion in funding from project partners that also includes global clean technology companies. Sustainable Development Technology Canada (SDTC) is energizing and evolving the development and demonstration of a clean technology ecosystem. They are the vital contributors to the prominent concentration of clean...